United States

Medpace opens new clinical pharmacology unit, expanding phase I-IIa capabilities

Thursday, July 19, 2012 01:44 PM

Cincinnati-based Medpace has opened the Medpace Clinical Pharmacology Unit (CPU) in Cincinnati. The new 60,000-square-foot facility is double the size of the previous unit, increasing Medpace’s ability to conduct multiple studies with a total of 96 beds for overnight stays. The facility houses a pharmacy, processing labs and a dedicated patient recruitment staff for recruitment and screening of study subjects. The new CPU joins the Medpace global headquarters and the Medpace CRO.

More... »

Conatus Pharmaceuticals appoints Morris as head of biostatistics

Thursday, July 19, 2012 08:16 AM

Conatus Pharmaceuticals, a San Diego-based privately held biopharmaceutical company focused on fibrotic disease and oncology, has appointed Mark F. Morris as head of biostatistics.

More... »

MedImmune to close vaccines sites in California

Tuesday, July 17, 2012 02:55 PM

Gaithersburg, Md.-based MedImmune, the global biologics arm of AstraZeneca, is restructuring its infectious disease and vaccines research, development and operations, closing its Mountain View, Calif., and Santa Clara, Calif., sites and consolidating its infectious disease and vaccines R&D to other existing sites. The changes are expected to be completed in 2014.

More... »

Biogen Idec to collaborate to sequence genomes of ALS patients

Tuesday, July 17, 2012 02:54 PM

Biogen Idec has entered into a research collaboration with premier academic and research institutions to sequence the genomes of up to 1,000 patients with amyotrophic lateral sclerosis (ALS) in an effort to gain a deeper understanding about the fundamental genetic causes of ALS.

More... »

ERT granted patents on clinical trial participant compliance

Tuesday, July 17, 2012 02:42 PM

Philadelphia-based ERT, a global technology-driven provider of health outcomes services to sponsors and CROs, has received two additional patents from the U.S. Patent and Trademark Office (U.S. Patent No. 8,065,180 and U.S. Patent No. 8,145,519).  The patents are titled System for Clinical Trial Subject Compliance and were acquired by ERT as part of its recent acquisition of invivodata.

More... »

Mission Search International to acquire Moxie Search Group

Tuesday, July 17, 2012 12:14 PM

Tampa, Fla.-based Mission Search International, a healthcare search and physician staffing firm, will acquire Moxie Search Group.

More... »

RxAlly names Tom O'Grady to leadership team

Tuesday, July 17, 2012 12:12 PM

RxAlly, a first-of-its-kind alliance of more than 22,000 pharmacies nationwide, has named Tom O'Grady to its leadership team.  As general counsel and executive vice president of corporate development, O’Grady brings more than 30 years of corporate and transactional law experience. He will be structuring business relationships between RxAlly and the companies and businesses it will be working with as it continues to align pharmacies and pharmacists, the patients they serve and the payer community.

More... »

Kala Pharmaceuticals appoints Pfefer as president and CEO

Tuesday, July 17, 2012 08:09 AM

Kala Pharmaceuticals, a Waltham, Mass.-based developer of products that rapidly penetrate the mucosal barrier to treat a wide range of debilitating diseases, has appointed Guillaume Pfefer, PhD, as president, CEO and member of the board of directors.

More... »

PharmaNet/i3 names VP and general manager, neuroscience

Monday, July 16, 2012 11:05 AM

PharmaNet/i3, inVentiv Health’s clinical segment, has appointed Robert Lasser, M.D., MBA, vice president and general manager, neuroscience, overseeing the management of all clinical projects handled by PharmaNet/i3’s neuroscience group and the Rater Training Services team. Dr. Lasser will be based in Princeton, N.J.

More... »

Orexigen Therapeutics shortens timeline with fast enrollment in Light study

Friday, July 13, 2012 08:52 AM

Orexigen Therapeutics, a La Jolla, Calif.-based biopharmaceutical company focused on the treatment of obesity, now expects to complete enrollment of patients required for the interim analysis of the Light study in the first quarter of 2013, potentially reducing original projections by half.

More... »